Syros Pharmaceuticals Inc (SYRS)
5.11
+0.11
(+2.20%)
USD |
NASDAQ |
May 31, 16:00
5.10
-0.01
(-0.20%)
After-Hours: 20:00
Syros Pharmaceuticals Research and Development Expense (Annual): 108.15M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 108.15M |
| December 31, 2022 | 111.94M |
| December 31, 2021 | 99.87M |
| December 31, 2020 | 76.06M |
| December 31, 2019 | 58.24M |
| Date | Value |
|---|---|
| December 31, 2018 | 50.18M |
| December 31, 2017 | 41.90M |
| December 31, 2016 | 37.82M |
| December 31, 2015 | 24.41M |
| December 31, 2014 | 10.92M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
58.24M
Minimum
2019
111.94M
Maximum
2022
90.86M
Average
99.87M
Median
2021
Research and Development Expense (Annual) Benchmarks
| PDS Biotechnology Corp | 27.76M |
| PAVmed Inc | 14.28M |
| Moderna Inc | 4.845B |
| Altimmune Inc | 65.80M |
| iBio Inc | 10.33M |